Amin Esmaeilnia Shirvani

Dr. Amin Esmaeilnia Shirvani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in Annals of Medicine
Verified
Journal Article
Open access
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKimia Pakdaman
Kimia Pakdaman
ZMZahra Maleki
Zahra Maleki
SSSoroush Soraneh
Soroush Soraneh
FCFatemeh Rezaei Chegini
Fatemeh Rezaei Chegini
PEPouyan Ebrahimi
Pouyan Ebrahimi
Haemorrhoidal disease (HD) is one of the most common anorectal disorders globally, significantly impacting individuals' quality of life and productivity. Despite its importance, global prevalence remains unclear due to limited population-specific studies. This study aimed to systematically assess the global prevalence of HD through a systematic review and meta-analysis. We conducted a systematic review and meta-analysis by searching PubMed, Scopus, Embase, Web of Science, and Google Scholar up to March 31, 2025, without language restrictions. Studies reporting prevalence of haemorrhoids in general, clinical, or high-risk populations were included. Exclusion criteria comprised studies lacking total sample size, focusing on other anorectal conditions, or using duplicate or insufficient data. Four independent reviewers extracted and appraised study quality using the Joanna Briggs Institute tool. The primary outcome was pooled point prevalence of HD, analyzed using a random-effects model with 95% confidence intervals (CIs). The study was registered in PROSPERO (CRD420251045600). From 6,312 records, 150 studies (210 datasets) comprising 8,960,338 individuals were included. The global pooled point prevalence was 25.92% (95% CI: 22.62-29.22). Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men, and highest in the African region 28.07% (95% CI: 15.34-40.79). Invasive diagnostic methods (28.05%, 95% CI: 23.86-32.26) yielded higher prevalence estimates than non-invasive methods. Also, factors showing associations with HD in unadjusted analyses include older age, obesity, pregnancy, diabetes, family history, constipation, and hypertension. HD remains a prevalent condition globally, with minor variation across regions. The burden is consistent regardless of socioeconomic context. Diagnostic method and population characteristics influence prevalence estimates. These findings underscore the importance of targeted prevention and early intervention strategies, especially for at-risk groups.

19 December 2025 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
MSMalihe Nourollahpour Shiadeh
Malihe Nourollahpour Shiadeh
KPKimia Pakdaman
Kimia Pakdaman
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
ZHZeinab Hashemi
Zeinab Hashemi
PEPouyan Ebrahimi
Pouyan Ebrahimi
Stroke is a leading cause of death and disability worldwide, with its prevalence increasing due to risk factors such as hypertension, diabetes, and hyperli

26 November 2025 in Cancer Reports
Verified
Journal Article
Open access
KPKimia Pakdaman
Kimia Pakdaman
AAAmirhossein Alizadeh‐Nodehi
Amirhossein Alizadeh‐Nodehi
ALAmir‐Hossein Lashkarbolouki
Amir‐Hossein Lashkarbolouki
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKasra Pakdaman
Kasra Pakdaman
PEPouyan Ebrahimi
Pouyan Ebrahimi
Background: Cervical cancer (CC) remains the fourth most prevalent malignancy among women globally, with a disproportionate burden in low‐ and middle‐income countries, where it is often diagnosed at advanced or metastatic stages. Aims: Despite an increasing number of case reports and institutional studies on brain metastases (BMs) arising from CC, current understanding of their epidemiology, clinical presentation, and prognostic implications remains fragmented and lacks comprehensive synthesis. Methods: We executed a systematic and unrestricted search of five major databases, PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar, covering all records up to April 19, 2025. Studies were eligible for inclusion if they provided a clear report on the incidence of BMs among CC patients. The quality and risk of bias of the selected studies were independently appraised using the Joanna Briggs Institute (JBI) assessment criteria. For statistical analysis, we utilized STATA version 17, implementing random‐effects meta‐analytical models to estimate the aggregated incidence along with corresponding 95% confidence intervals (CIs). Results: A total of 17 studies encompassing 33 datasets were included in the final analysis. The global pooled incidence of BMs among cervical cancer patients was estimated at 0.65% (95% CI: 0.46–0.85). Incidence was highest in Turkey (1.83%, 95% CI: 0.91–2.75) and lowest in South Africa (0.22%, 95% CI: 0.0–0.47). Among histologic subtypes, neuroendocrine carcinoma exhibited the highest pooled incidence of BMs at 10.60% (95% CI: 0.0–21.63), followed by adenocarcinoma at 0.89% (95% CI: 0.14–1.64). The pooled mean survival time following the diagnosis of BMs was 6.80 months (95% CI: 5.08–8.52), while the mean interval from the initial cervical cancer diagnosis to the development of BMs was 28.15 months (95% CI: 24.27–32.03). Conclusion: Although BMs in cervical cancer are rare, they are associated with dismal survival outcomes and poor prognosis. These findings underscore the importance of vigilant surveillance in high‐risk patients and may inform the development of more targeted and effective therapeutic and preventive strategies.

28 August 2025 in Cancer Control
Verified
Journal Article
Open access
KPKimia Pakdaman
Kimia Pakdaman
HNHossein-Ali Nikbakht
Hossein-Ali Nikbakht
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
SSSaba Sahraian
Saba Sahraian
LSLayla Shojaie
Layla Shojaie
PEPouyan Ebrahimi
Pouyan Ebrahimi
Introduction: Cancer is a significant worldwide health problem, and targeted drugs like Cabozantinib and Atezolizumab offer new therapeutic options. These drugs enhance patient survival by specifically targeting cancer cells while minimizing damage to healthy tissues. The current research investigates the effectiveness of employing the combination of Cabozantinib and Atezolizumab vs single-agent Cabozantinib. Methods: In this study, we searched databases including PubMed/Medline, Scopus, Embase, Cochrane, and Web of Science up to the end of January 2025. The results were categorized into two groups: the intervention group (Cabozantinib plus Atezolizumab) and the control group (Cabozantinib monotherapy) in cancer patients. We evaluated variables such as efficacy outcomes, including Objective Response Rate (ORR) and Disease Control Rate (DCR), as well as adverse events (safety). Data analysis was performed using random-effects models, and Relative Risk (RR) was reported as the effect size. Results: Three clinical trials were included in this study. Regarding efficacy outcomes, there was no statistically significant difference in ORR between the intervention group and the control group (RR = 1.11, 95% CI: 0.76-1.61). Similarly, DCR did not differ significantly between groups (RR = 0.98, 95% CI: 0.94-1.03). In terms of safety, the combination therapy was associated with a statistically significant reduction in four treatment-related adverse events: diarrhea (RR = 0.91, 95% CI: 0.83-0.99), nausea (RR = 0.79, 95% CI: 0.65-0.95), vomiting (RR = 0.70, 95% CI: 0.52-0.96), and hypokalemia (RR = 0.28, 95% CI: 0.19-0.40). Conclusion: The findings suggest that the combination of Cabozantinib and Atezolizumab does not offer significant improvement in treatment efficacy compared to Cabozantinib alone. However, the combination may be associated with a lower incidence of certain chemotherapy-related adverse events. These exploratory findings may inform future research on treatment strategies for patients who experience intolerance to Cabozantinib monotherapy.

27 December 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
KPKimia Pakdaman
Kimia Pakdaman
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKasra Pakdaman
Kasra Pakdaman
BKBardia Karim
Bardia Karim
SSSaba Sahraian
Saba Sahraian
PEPouyan Ebrahimi
Pouyan Ebrahimi
Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.

3 November 2026 in BMC Cancer
Verified
Journal Article
Open access
AKAnita Khalili
Anita Khalili
ATAlireza Taghizadeh
Alireza Taghizadeh
ASAmir Morteza Soleimani
Amir Morteza Soleimani
MSMohsen Sadeghi
Mohsen Sadeghi
BEBehrad Eftekhari
Behrad Eftekhari
PEPouyan Ebrahimi
Pouyan Ebrahimi
Background: Lung metastasis (LM) is a clinically significant manifestation of breast cancer (BC), yet its incidence across diverse populations remains insufficiently characterized. This study aimed to estimate the pooled reported proportion of LM and explore potential sources of heterogeneity. Methods: This systematic review and meta-analysis was conducted following PRISMA guidelines and prospectively registered in PROSPERO (CRD420251275241). PubMed, Scopus, Embase, Web of Science, and Google Scholar were systematically searched from inception to September 30, 2026, without language restrictions. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Joanna Briggs Institute checklist. Pooled LM proportions were estimated using a random-effects model with restricted maximum likelihood (REML) estimation and logit-transformed proportions. Subgroup analyses, meta-regression, and sensitivity analyses were performed to explore heterogeneity and assess the robustness of the findings. Results: Seventeen studies comprising 1,023,998 BC patients and 10,685 reported LM cases were included. The pooled reported LM proportion was 2.68% (95% CI: 1.40–5.07%), with substantial heterogeneity (I² = 99.87%). Subtype-specific pooled point estimates were 4.53% for HR−/HER2+, 3.86% for TNBC, 2.22% for HR+/HER2+, and 1.33% for HR+/HER2 − disease; however, the overall between-subgroup difference was not statistically significant ( p = 0.520). Subgroup analyses revealed significant differences across WHO regions ( p < 0.001), PM2.5 categories ( p = 0.002), and risk-of-bias classifications ( p = 0.012), whereas HDI, income level, study design, and publication year showed no significant between-group differences. The six primary moderators showed no significant associations in univariable meta-regression. Despite significant differences across PM2.5 categories in subgroup analyses, neither continuous PM2.5 nor AQI was significantly associated with LM proportion in the exploratory multivariable model (PM2.5: β = −0.272, p = 0.317; AQI: β = 0.108, p = 0.389). An inverse association between HDI and the reported LM proportion emerged only in the exploratory multivariable model (β = −12.924, p = 0.040) and should be interpreted cautiously given the limited number of studies and potential multicollinearity. Conclusion: The pooled reported proportion of LM among BC patients was approximately 2.7%, with considerable heterogeneity across studies. Although geographical and environmental subgroup differences were observed, the inconsistency of study-level associations warrants cautious interpretation. Standardized metastatic-site reporting and improved epidemiological surveillance are essential for more reliable estimates. Clinical trial registration: Not applicable.